阿帕他胺联合ADT治疗转移性激素敏感性前列腺癌的疗效

Efficacy of apalutamide combined with ADT in the treatment of metastatic hormone-sensitive prostate cancer

目的评估阿帕他胺联合雄激素剥夺疗法(ADT)治疗转移性激素敏感性前列腺癌(mHSPC)的疗效。方法回顾性分析接受阿帕他胺联合ADT治疗的53例mHSPC患者的临床资料,并对患者进行6个月的随访,评估患者治疗后前列腺特异抗原(PSA)缓解率、肿瘤最大横径变化及药物不良反应发生的情况。结果治疗6个月后,所有患者血清PSA水平较治疗前下降超过50%,51例(96.23%)患者血清PSA水平较治疗前下降超过90%。14例行盆腔前列腺增强MRI随访的患者治疗6个月后肿瘤最大横径较治疗前减小[(23.87±10.58)mmvs.(47.00±21.93)mm](P<0.05)。53例患者中,8例(15.09%)患者出现不同程度的皮疹,11例(20.75%)患者出现乏力、食欲下降。结论阿帕他胺联合ADT治疗mHSPC患者具有良好的PSA应答率和安全性,能有效缩小肿瘤横径。

Objective To evaluate the efficacy of apalutamide combined with androgen deprivation therapy(ADT)in the treatment of metastatic hormone-sensitive prostate cancer(mHSPC).Methodss The clinical data of 53 mHSPC patients received apalutamide combined with ADT treatment were retrospectively analyzed.The response rate of prostate specific antigen(PSA),changes in maximum tumor diameter and occurrence of adverse drug reactions after treatment were evaluated after follow-up for 6 months.Results Compared to the initial PSA before treatment,after 6 months of treatment,serum PSA levels of all patients were decreased by more than 50%,and serum PSA levels of 51(96.23%)patients were decreased by more than 90%.Fourteen patients were followed up with prostate enhanced MRI,the maximum tumor diameter of the lesion was decreased after treatment compared to that before treatment[(23.87±10.58)mm vs.(47.00±21.93)mm](P<0.05).Of 53 patients,8(15.09%)cases experienced varying degrees of rash,and 11(20.75%)cases experienced fatigue and decreased appetite.Conclusion Apalutamide combined with ADT treatment has a good PSA response rate and safety in the patients with mHSPC,which can effectively reduce the tumor diameter.